Shares of Amgen broke out of a consolidation with a buy point at 245.09 on July 1 after the biotech company won a patent battle over its blockbuster drug Enbrel.In late May, Amgen unveiled updated data showing 12% of patients with colon cancer and a KRAS mutation objectively responded to a 960-milligram once daily dose.